Endocrinology and Metabolism

Chang-Myung Oh (Oh 1)

4 Articles

Diabetes, Obesity and Metabolism
Serotonergic Regulation of Hepatic Energy Metabolism: Jiwon Park, Wooju Jeong, Chahyeon Yun, Hail Kim, Chang-Myung Oh; Endocrinol Metab. 2021;36(6):1151-1160. Published online December 16, 2021; DOI: https://doi.org/10.3803/EnM.2021.1331

6,004 View
220 Download
7 Web of Science
8 Crossref

The liver is a vital organ that regulates systemic energy metabolism and many physiological functions. Nonalcoholic fatty liver disease (NAFLD) is the commonest cause of chronic liver disease and end-stage liver failure. NAFLD is primarily caused by metabolic disruption of lipid and glucose homeostasis. Serotonin (5-hydroxytryptamine [5-HT]) is a biogenic amine with several functions in both the central and peripheral systems. 5-HT functions as a neurotransmitter in the brain and a hormone in peripheral tissues to regulate systemic energy homeostasis. Several recent studies have proposed various roles of 5-HT in hepatic metabolism and inflammation using tissue-specific knockout mice and 5-HT-receptor agonists/antagonists. This review compiles the most recent research on the relationship between 5-HT and hepatic metabolism, and the role of 5-HT signaling as a potential therapeutic target in NAFLD.

Citations

Citations to this article as recorded by

Maternal nutrient metabolism in the liver during pregnancy
Hongxu Fang, Qingyang Li, Haichao Wang, Ying Ren, Leying Zhang, Ling Yang
Frontiers in Endocrinology.2024;[Epub] CrossRef
Neural Stem Cell-based Regenerative Therapy: A New Approach to Diabetes Treatment
Kajal Sharma, Nidhi Puranik, Dhananjay Yadav
Endocrine, Metabolic & Immune Disorders - Drug Targets.2024; 24(5): 531. CrossRef
Metabolic and Molecular Response to High-Fat Diet Differs between Rats with Constitutionally High and Low Serotonin Tone
Petra Baković, Maja Kesić, Darko Kolarić, Jasminka Štefulj, Lipa Čičin-Šain
International Journal of Molecular Sciences.2023; 24(3): 2169. CrossRef
Roles of gut microbes in metabolic-associated fatty liver disease
Chun-Yao Chen, Han-Chen Ho
Tzu Chi Medical Journal.2023; 35(4): 279. CrossRef
Imidazoles as Serotonin Receptor Modulators for Treatment of Depression: Structural Insights and Structure–Activity Relationship Studies
Kapil Kumar Goel, Somesh Thapliyal, Rajeev Kharb, Gaurav Joshi, Arvind Negi, Bhupinder Kumar
Pharmaceutics.2023; 15(9): 2208. CrossRef
Serotonin in the regulation of systemic energy metabolism
Joon Ho Moon, Chang‐Myung Oh, Hail Kim
Journal of Diabetes Investigation.2022; 13(10): 1639. CrossRef
Involvement of the liver-gut peripheral neural axis in nonalcoholic fatty liver disease pathologies via hepatic HTR2A
Takashi Owaki, Kenya Kamimura, Masayoshi Ko, Itsuo Nagayama, Takuro Nagoya, Osamu Shibata, Chiyumi Oda, Shinichi Morita, Atsushi Kimura, Takeki Sato, Toru Setsu, Akira Sakamaki, Hiroteru Kamimura, Takeshi Yokoo, Shuji Terai
Disease Models & Mechanisms.2022;[Epub] CrossRef
Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines
Anwesha Gangopadhyay, Radwa Ibrahim, Karli Theberge, Meghan May, Karen L. Houseknecht
Frontiers in Neuroscience.2022;[Epub] CrossRef

Diabetes, Obesity and Metabolism
Efficacy and Safety of the New Appetite Suppressant, Liraglutide: A Meta-Analysis of Randomized Controlled Trials: Shinje Moon, Jibeom Lee, Hye Soo Chung, Yoon Jung Kim, Jae Myung Yu, Sung Hoon Yu, Chang-Myung Oh; Endocrinol Metab. 2021;36(3):647-660. Published online June 18, 2021; DOI: https://doi.org/10.3803/EnM.2020.934

6,198 View
302 Download
13 Web of Science
14 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Obesity is a chronic disease associated with metabolic diseases such as diabetes and cardiovascular disease. Since the U.S. Food and Drug Administration approved liraglutide as an anti-obesity drug for nondiabetic patients in 2014, it has been widely used for weight control in overweight and obese people. This study aimed to systematically analyze the effects of liraglutide on body weight and other cardiometabolic parameters.
Methods
We investigated articles from PubMed, EMBASE, and the Cochrane Library to search randomized clinical trials that examined body weight changes with liraglutide treatment.
Results
We included 31 studies with 8,060 participants for this meta-analysis. The mean difference (MD) between the liraglutide group and the placebo group was −4.19 kg (95% confidence interval [CI], −4.84 to −3.55), with a −4.16% change from the baseline (95% CI, −4.90 to −3.43). Liraglutide treatment correlated with a significantly reduced body mass index (MD: −1.55; 95% CI, −1.76 to −1.34) and waist circumference (MD: −3.11 cm; 95% CI, −3.59 to −2.62) and significantly decreased blood pressure (systolic blood pressure, MD: −2.85 mm Hg; 95% CI, −3.36 to −2.35; diastolic blood pressure, MD: −0.66 mm Hg; 95% CI, −1.02 to −0.30), glycated hemoglobin (MD: −0.40%; 95% CI, −0.49 to −0.31), and low-density lipoprotein cholesterol (MD: –2.91 mg/dL; 95% CI, −5.28 to −0.53; MD: −0.87% change from baseline; 95% CI, −1.17 to −0.56).
Conclusion
Liraglutide is effective for weight control and can be a promising drug for cardiovascular protection in overweight and obese people.

Citations

Citations to this article as recorded by

Pharmacotherapy for obesity: moving towards efficacy improvement
Walmir Coutinho, Bruno Halpern
Diabetology & Metabolic Syndrome.2024;[Epub] CrossRef
Physiopathology and Treatment of Obesity and Overweight: A Proposal for a New Anorectic
Bruno Silvestrini, Mauro Silvestrini, Mayank Choubey
Journal of Obesity.2024; 2024: 1. CrossRef
Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis
Yilin Li, Rong Lei, Honglin Lei, Qin Xiong, Fengjiao Xie, Chengjiao Yao, Peimin Feng
European Journal of Gastroenterology & Hepatology.2023; 35(1): 1. CrossRef
Recommendations for the prevention and management of obesity in the Iraqi population
Hussein Ali Nwayyir, Esraa Majid Mutasher, Osama Mohammed Alabid, Muthana Abdulrazzaq Jabbar, Wefak Hasan Abdulraheem Al-Kawaz, Haider Ayad Alidrisi, Majid Alabbood, Muhammed Chabek, Munib AlZubaidi, Lujain Anwar Al-khazrajy, Ibtihal Shukri Abd Alhaleem,
Postgraduate Medicine.2023; 135(5): 425. CrossRef
A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications
Fatma Haddad, Ghadeer Dokmak, Maryam Bader, Rafik Karaman
Life.2023; 13(4): 1012. CrossRef
Liraglutide, a glucagon-like peptide-1 analog, in individuals with obesity in clinical practice
Juyoung Shin, Raeun Kim, Hun-Sung Kim
Cardiovascular Prevention and Pharmacotherapy.2023; 5(2): 49. CrossRef
The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
Pejman Rohani, Nasser Malekpour Alamdari, Seyedeh Elaheh Bagheri, Azita Hekmatdoost, Mohammad Hassan Sohouli
Frontiers in Endocrinology.2023;[Epub] CrossRef
Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials
Hao Gou, Yiman Zhai, Junjun Guo
European Journal of Pediatrics.2023; 182(11): 5095. CrossRef
Efficacy and safety of once-weekly semaglutide in adults with overweight or obesity: a meta-analysis
Ping Zhong, Hai Zeng, Miaochun Huang, Wenbin Fu, Zhixia Chen
Endocrine.2022; 75(3): 718. CrossRef
Pharmacological profile of once-weekly injectable semaglutide for chronic weight management
David C. W. Lau, Rachel L Batterham, Carel W. le Roux
Expert Review of Clinical Pharmacology.2022; 15(3): 251. CrossRef
Pharmacological Management of Obesity: A Century of Expert Opinions in Cecil Textbook of Medicine
Peter Manu, Cristina-Mihaela Lăcătuşu, Liliana M. Rogozea, Simona Cernea
American Journal of Therapeutics.2022; 29(4): e410. CrossRef
GLP-1 agonists: superior for mind and body in antipsychotic-treated patients?
Katerina Horska, Jana Ruda-Kucerova, Silje Skrede
Trends in Endocrinology & Metabolism.2022; 33(9): 628. CrossRef
Targeting skeletal muscle mitochondrial health in obesity
Chantal A. Pileggi, Breana G. Hooks, Ruth McPherson, Robert R.M. Dent, Mary-Ellen Harper
Clinical Science.2022; 136(14): 1081. CrossRef
A Study on Weight Loss Cause as per the Side Effect of Liraglutide
Jin Yu, Jeongmin Lee, Seung-Hwan Lee, Jae-Hyung Cho, Hun-Sung Kim, Heng Zhou
Cardiovascular Therapeutics.2022; 2022: 1. CrossRef

Miscellaneous
Erratum: Correction of Figure. Serotonin Regulates De Novo Lipogenesis in Adipose Tissues through Serotonin Receptor 2A: Ko Eun Shong, Chang-Myung Oh, Jun Namkung, Sangkyu Park, Hail Kim; Endocrinol Metab. 2020;35(3):672. Published online August 6, 2020; DOI: https://doi.org/10.3803/EnM.2020.307; Corrects: Endocrinol Metab 2020;35(2):470

3,958 View
85 Download

PDF PubReader ePub

Endocrine Research
Serotonin Regulates De Novo Lipogenesis in Adipose Tissues through Serotonin Receptor 2A: Ko Eun Shong, Chang-Myung Oh, Jun Namkung, Sangkyu Park, Hail Kim; Endocrinol Metab. 2020;35(2):470-479. Published online June 24, 2020; DOI: https://doi.org/10.3803/EnM.2020.35.2.470; Correction in: Endocrinol Metab 2020;35(3):672

8,514 View
262 Download
21 Web of Science
20 Crossref

Abstract PDF Supplementary Material PubReader ePub

Background
Obesity is defined as excessive fat mass and is a major cause of many chronic diseases such as diabetes, cardiovascular disease, and cancer. Increasing energy expenditure and regulating adipose tissue metabolism are important targets for the treatment of obesity. Serotonin (5-hydroxytryptophan [5-HT]) is a monoamine metabolite of the essential amino acid tryptophan. Here, we demonstrated that 5-HT in mature adipocytes regulated energy expenditure and lipid metabolism.
Methods
Tryptophan hydroxylase 1 (TPH1) is the rate-limiting enzyme during 5-HT synthesis in non-neural peripheral tissues. We generated adipose tissue-specific Tph1 knockout (Tph1 FKO) mice and adipose tissue-specific serotonin receptor 2A KO (Htr2a FKO) mice and analyzed their phenotypes during high-fat diet (HFD) induced obesity.
Results
Tph1 FKO mice fed HFD exhibited reduced lipid accumulation, increased thermogenesis, and resistance to obesity. In addition, Htr2a FKO mice fed HFD showed reduced lipid accumulation in white adipose tissue and resistance to obesity.
Conclusion
These data suggest that the inhibition of serotonin signaling might be an effective strategy in obesity.

Citations

Citations to this article as recorded by

Gut microbiota dysbiosis and decreased levels of acetic and propionic acid participate in glucocorticoid-induced glycolipid metabolism disorder
Qin Zhang, Gaopeng Guan, Jie Liu, Wenmu Hu, Ping Jin, Yung-Fu Chang
mBio.2024;[Epub] CrossRef
The Chain-Mediating Effect of Obesity, Depressive Symptoms on the Association between Dietary Quality and Cardiovascular Disease Risk
Shuai Zhang, Limei E, Zhonghai Lu, Yingying Yu, Xuebin Yang, Yao Chen, Xiubo Jiang
Nutrients.2023; 15(3): 629. CrossRef
Metabolic and Molecular Response to High-Fat Diet Differs between Rats with Constitutionally High and Low Serotonin Tone
Petra Baković, Maja Kesić, Darko Kolarić, Jasminka Štefulj, Lipa Čičin-Šain
International Journal of Molecular Sciences.2023; 24(3): 2169. CrossRef
Linking serotonin homeostasis to gut function: Nutrition, gut microbiota and beyond
Lili Jiang, Dandan Han, Youling Hao, Zhuan Song, Zhiyuan Sun, Zhaolai Dai
Critical Reviews in Food Science and Nutrition.2023; : 1. CrossRef
Serotonin transporter-deficient mice display enhanced adipose tissue inflammation after chronic high-fat diet feeding
Johannes Hoch, Niklas Burkhard, Shanshan Zhang, Marina Rieder, Timoteo Marchini, Vincent Geest, Krystin Krauel, Timm Zahn, Nicolas Schommer, Muataz Ali Hamad, Carolina Bauer, Nadine Gauchel, Daniela Stallmann, Claus Normann, Dennis Wolf, Rüdiger Eberhard
Frontiers in Immunology.2023;[Epub] CrossRef
The role of serotonin in prenatal ontogenesis
Inna I. Evsyukova
Journal of obstetrics and women's diseases.2023; 72(4): 81. CrossRef
Genome-wide survey and functional analysis reveal TCF21 promotes chicken preadipocyte differentiation by directly upregulating HTR2A
Xinyang Zhang, Bohan Cheng, Yanyan Ma, Yumeng Liu, Ning Wang, Hui Zhang, Yumao Li, Yuxiang Wang, Peng Luan, Zhiping Cao, Hui Li
Biochemical and Biophysical Research Communications.2022; 587: 131. CrossRef
Maternal Metabolic State and Fetal Sex and Genotype Modulate Methylation of the Serotonin Receptor Type 2A Gene (HTR2A) in the Human Placenta
Marina Horvatiček, Maja Perić, Ivona Bečeheli, Marija Klasić, Maja Žutić, Maja Kesić, Gernot Desoye, Sandra Nakić Radoš, Marina Ivanišević, Dubravka Hranilovic, Jasminka Štefulj
Biomedicines.2022; 10(2): 467. CrossRef
Synthesis and biological evaluation of tyrosine derivatives as peripheral 5HT2A receptor antagonists for nonalcoholic fatty liver disease
Minhee Kim, Wonil Choi, Jihyeon Yoon, Byung-kwan Jeong, Suvarna H. Pagire, Haushabhau S. Pagire, Jungsun Park, Jung Eun Nam, Chang Joo Oh, Jae-Han Jeon, Seong Soon Kim, Byung Hoi Lee, Jin Sook Song, Myung Ae Bae, In-Kyu Lee, Hail Kim, Jin Hee Ahn
European Journal of Medicinal Chemistry.2022; 239: 114517. CrossRef
Serotonin in the regulation of systemic energy metabolism
Joon Ho Moon, Chang‐Myung Oh, Hail Kim
Journal of Diabetes Investigation.2022; 13(10): 1639. CrossRef
Traumatic brain injury alters the gut-derived serotonergic system and associated peripheral organs
Natosha M. Mercado, Guanglin Zhang, Zhe Ying, Fernando Gómez-Pinilla
Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2022; 1868(11): 166491. CrossRef
Modulation of adipose tissue metabolism by microbial-derived metabolites
Wenyun Liu, Ge Yang, Pinyi Liu, Xin Jiang, Ying Xin
Frontiers in Microbiology.2022;[Epub] CrossRef
Risperidone Exacerbates Glucose Intolerance, Nonalcoholic Fatty Liver Disease, and Renal Impairment in Obese Mice
Hsiao-Pei Tsai, Po-Hsun Hou, Frank-Chiahung Mao, Chia-Chia Chang, Wei-Cheng Yang, Ching-Feng Wu, Huei-Jyuan Liao, Tzu-Chun Lin, Lan-Szu Chou, Li-Wei Hsiao, Geng-Ruei Chang
International Journal of Molecular Sciences.2021; 22(1): 409. CrossRef
Pancreatic Sirtuin 3 Deficiency Promotes Hepatic Steatosis by Enhancing 5-Hydroxytryptamine Synthesis in Mice With Diet-Induced Obesity
Xing Ming, Arthur C.K. Chung, Dandan Mao, Huanyi Cao, Baoqi Fan, Willy K.K. Wong, Chin Chung Ho, Heung Man Lee, Kristina Schoonjans, Johan Auwerx, Guy A. Rutter, Juliana C.N. Chan, Xiao Yu Tian, Alice P.S. Kong
Diabetes.2021; 70(1): 119. CrossRef
Peripheral Selective Oxadiazolylphenyl Alanine Derivatives as Tryptophan Hydroxylase 1 Inhibitors for Obesity and Fatty Liver Disease
Eun Jung Bae, Won Gun Choi, Haushabhau S. Pagire, Suvarna H. Pagire, Saravanan Parameswaran, Jun-Ho Choi, Jihyeon Yoon, Won-il Choi, Ji Hun Lee, Jin Sook Song, Myung Ae Bae, Mijin Kim, Jae-Han Jeon, In-Kyu Lee, Hail Kim, Jin Hee Ahn
Journal of Medicinal Chemistry.2021; 64(2): 1037. CrossRef
A Systems Biology Approach to Investigating the Interaction between Serotonin Synthesis by Tryptophan Hydroxylase and the Metabolic Homeostasis
Suhyeon Park, Yumin Kim, Jibeom Lee, Jeong Yun Lee, Hail Kim, Sunjae Lee, Chang-Myung Oh
International Journal of Molecular Sciences.2021; 22(5): 2452. CrossRef
Metabolic Disturbances in Rat Sublines with Constitutionally Altered Serotonin Homeostasis
Maja Kesić, Petra Baković, Ranko Stojković, Jasminka Štefulj, Lipa Čičin-Šain
International Journal of Molecular Sciences.2021; 22(10): 5400. CrossRef
The Mechanism of Secretion and Metabolism of Gut-Derived 5-Hydroxytryptamine
Ning Liu, Shiqiang Sun, Pengjie Wang, Yanan Sun, Qingjuan Hu, Xiaoyu Wang
International Journal of Molecular Sciences.2021; 22(15): 7931. CrossRef
Inhibiting serotonin signaling through HTR2B in visceral adipose tissue improves obesity-related insulin resistance
Won Gun Choi, Wonsuk Choi, Tae Jung Oh, Hye-Na Cha, Inseon Hwang, Yun Kyung Lee, Seung Yeon Lee, Hyemi Shin, Ajin Lim, Dongryeol Ryu, Jae Myoung Suh, So-Young Park, Sung Hee Choi, Hail Kim
Journal of Clinical Investigation.2021;[Epub] CrossRef
Serotonergic Regulation of Hepatic Energy Metabolism
Jiwon Park, Wooju Jeong, Chahyeon Yun, Hail Kim, Chang-Myung Oh
Endocrinology and Metabolism.2021; 36(6): 1151. CrossRef

Author index